Regeneron Pharmaceuticals, Inc and Bayer HealthCare AG has announced the result of Phase 2 trial of the VEGF Trap-Eye. It reported to have achieved durable improvements in visual acuity and in biologic measures of neovascular disease, including retinal thickness and active choroidal neovascularization lesion size.
In this double-masked Phase 2 trial, patients were initially treated with either fixed monthly or quarterly dosing for 12 weeks and then continued to receive treatment for another 40 weeks on a PRN (as needed) dosing schedule. Patients receiving monthly doses of VEGF Trap-Eye of either 2.0 or 0.5 milligrams (mg) for 12 weeks followed by PRN dosing achieved mean improvements in visual acuity versus baseline of 9.0 letters (p less than 0.0001 versus baseline) and 5.4 letters (p less than 0.085 versus baseline), respectively, at the end of one year.
At the end of the study, the patients receiving monthly doses of VEGF Trap-Eye of either 2.0 or 0.5 mg for 12 weeks followed by PRN dosing also achieved mean decreases in retinal thickness versus baseline of 143 microns (p less than 0.0001 versus baseline) and 125 microns (p less than 0.0001 versus baseline) at week 52, respectively.
Source: StreetInsider.com
Filed under Eye Treatment, Improved Vision | Tags: Bayer HealthCare AG, double-masked Phase 2 trial, neovascular disease, Regeneron Pharmaceuticals Inc, retinal thickness, VEGF Trap-Eye, visual acuity | Comment Below
Related?
Ocular diseases can be cured by new drug - VEGF Trap-EyeAugust 22nd, 2008 Latest study proves that particular dose of new drug named "VEGF Trap-Eye" on an as-needed basis can cure devastating ocular diseases. This was concluded by undergoing a phase-two study done by Bayer Healthcare AG and Regeneron Pharmaceuticals.
Bayer and Regenron Agreed to Jointly Develop Treatment for Eye DiseaseOctober 23rd, 2006 Bayer AG's Bayer Healthcare unit and Regeneron Pharmaceuticals Inc. agreed to jointly develop, and commercialize a treatment for eye disease.
Phase-II Clinical Trial of Drug Evizon for Wet Age-Related Macular DegenerationJune 28th, 2006 Biopharmaceutical company Genaera Corporation has commenced a multi-center phase II clinical trial to explore the efficacy and safety of higher doses of its investigational drug Evizon for the treatment of the eye disease, wet age-related macular degeneration. The study is designed to evaluate up to 140 patients with wet age-related macular degeneration (AMD) treated with Evizon at four dose levels of 40mg, 80mg, 120mg and 160mg over a 20 week period.
Lucentis promising hopes for retinal vein occlusion in Phase III trialJuly 7th, 2009 Genentech, Inc. announced recently that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to branch retinal vein occlusion.
Scripps Institute Researchers Offer New Drug For Vision LossMay 24th, 2008 A new study was approached by Martin Friedlander and colleagues, at the Scripps Institute, La Jolla, suggesting a simpler way to reduce VEGF induced blood vessel in the eye which causes vision loss. In most disease, vision loss is caused, when the permeability of blood vessels in the retina of eye is alerted by other factors (e.g, fluid accumulating in the retina impairing eyesight).
Phase II Clinical Trial of Mifepristone an Eye Drop Treatment for Steroid Associated Elevated Intraocular PressureSeptember 27th, 2006 Global bio-nanotech company pSivida Limited (NASDAQ:PSDV) (ASX:PSD) (Xetra:PSI) today announced the initiation of a Phase II clinical trial of Mifepristone (otherwise known as RU486) as an eye drop treatment for steroid associated elevated intraocular pressure (IOP). The investigator-sponsored trial will involve up to 45 patients in the United States.
Dry age-related macular degeneration (AMD) can be treated by Acucela's visual cycle modulator ACU-4429June 24th, 2009 Acucela Inc. is a clinical-stage biotechnology company, presently focusing on visual cycle modulation (VCM) to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwide.
After UK, US researchers successfull in using gene therapy to cure inherited sight disorderSeptember 24th, 2008 US scientists have claimed to be successful in gene therapy by injected material containing a corrective gene into the eyes of three patients with Leber congenital amaurosis (LCA). The journal Proceedings of the National Academy of Sciences reports significant improvement in their eyes.
